scholarly journals Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model

2015 ◽  
Vol 59 (12) ◽  
pp. 7255-7264 ◽  
Author(s):  
Amber Farooqui ◽  
Linxi Huang ◽  
Suwu Wu ◽  
Yingmu Cai ◽  
Min Su ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Infection ◽  
Mouse Model ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Antiviral Treatment ◽  
Clinical Signs ◽  
Influenza Virus Infection ◽  
H7n9 Influenza Virus ◽  
H7n9 Influenza

ABSTRACTThe H7N9 influenza virus causes a severe form of disease in humans. Neuraminidase inhibitors, including oral oseltamivir and injectable peramivir, are the first choices of antiviral treatment for such cases; however, the clinical efficacy of these drugs is questionable. Animal experimental models are essential for understanding the viral replication kinetics under the selective pressure of antiviral agents. This study demonstrates the antiviral activity of peramivir in a mouse model of H7N9 avian influenza virus infection. The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection. Early treatment with peramivir was found to be associated with better disease outcomes.

scholarly journals Ramsay Hunt Syndrome in a Patient with H7N9 Influenza Virus Infection

2015 ◽  
Vol 128 (3) ◽  
pp. 417-418
Author(s):  
Jia-Jia Wang ◽  
Jian-An Huang ◽  
Da-Guo Zhao ◽  
Jun Jin ◽  
Sheng-Lan Liu ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Infection ◽  
Influenza Virus Infection ◽  
Ramsay Hunt Syndrome ◽  
Hunt Syndrome ◽  
H7n9 Influenza Virus ◽  
H7n9 Influenza

scholarly journals DNA Vaccine Encoding Hemagglutinin Provides Protective Immunity against H5N1 Influenza Virus Infection in Mice

1999 ◽  
Vol 73 (3) ◽  
pp. 2094-2098 ◽  
Author(s):  
Shantha Kodihalli ◽  
Hideo Goto ◽  
Darwyn L. Kobasa ◽  
Scott Krauss ◽  
Yoshihiro Kawaoka ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Infection ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Dna Vaccine ◽  
Influenza Virus Infection ◽  
Glycosylation Site ◽  
Mammalian Host ◽  
H5n1 Infection ◽  
H5n1 Avian Influenza

ABSTRACT In Hong Kong in 1997, a highly lethal H5N1 avian influenza virus was apparently transmitted directly from chickens to humans with no intermediate mammalian host and caused 18 confirmed infections and six deaths. Strategies must be developed to deal with this virus if it should reappear, and prospective vaccines must be developed to anticipate a future pandemic. We have determined that unadapted H5N1 viruses are pathogenic in mice, which provides a well-defined mammalian system for immunological studies of lethal avian influenza virus infection. We report that a DNA vaccine encoding hemagglutinin from the index human influenza isolate A/HK/156/97 provides immunity against H5N1 infection of mice. This immunity was induced against both the homologous A/HK/156/97 (H5N1) virus, which has no glycosylation site at residue 154, and chicken isolate A/Ck/HK/258/97 (H5N1), which does have a glycosylation site at residue 154. The mouse model system should allow rapid evaluation of the vaccine’s protective efficacy in a mammalian host. In our previous study using an avian model, DNA encoding hemagglutinin conferred protection against challenge with antigenic variants that differed from the primary antigen by 11 to 13% in the HA1 region. However, in our current study we found that a DNA vaccine encoding the hemagglutinin from A/Ty/Ir/1/83 (H5N8), which differs from A/HK/156/97 (H5N1) by 12% in HA1, prevented death but not H5N1 infection in mice. Therefore, a DNA vaccine made with a heterologous H5 strain did not prevent infection by H5N1 avian influenza viruses in mice but was useful in preventing death.

Sign in / Sign up

Export Citation Format

Share Document